DFIB Cardiac Science (MM)

Mexicana Airlines Purchases Cardiac Science AEDs for Commercial Airliner Fleet IRVINE, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. (NASDAQ:DFIB), a leading manufacturer of life-saving automated public access defibrillators (AEDs) and provider of comprehensive AED/CPR training services, today announced that Mexicana Airlines has purchased 60 Powerheart(R) G3 AEDs for installation and use in their fleet of commercial airliners. Mexicana joins other domestic and international airlines that have deployed Cardiac Science AEDs including SkyWest Airlines, Atlantic Coast Airlines, Japan Airlines, Japan Air Systems, Malev Hungarian airlines and Saudi Arabian Airlines. Cardiac Science Chairman and CEO Raymond W. Cohen said the life-saving AEDs are being deployed on Mexicana national and international flights and that passengers on flights with AEDs can rest assured that they are well protected should they suffer sudden cardiac arrest. Mexicana Airlines transports passengers between 53 destinations in North, Central, South America, the Caribbean and Europe and is the international airline leader for travel between the U.S. and Mexico. About Cardiac Science Cardiac Science develops, manufactures and markets Powerheart(R)-brand public-access defibrillators (AEDs) and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. Cardiac Science also manufactures its AED products on a private label basis for other leading medical companies such as Nihon Kohden (Japan), Quinton Cardiology Systems and GE Healthcare. For more information, please visit http://www.cardiacscience.com/. This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, from time to time the company, or its representatives, have made or may make forward looking statements orally or in writing. The words "estimate," "potential," "intended," "expect," "anticipate," "believe," and other similar expressions or words are intended to identify forward looking statements. Such forward-looking statements include, but are not limited to the achievement of future revenue growth and other expected financial results. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the company's Form 10-K for the year ended December 31, 2003, subsequent quarterly filings, and other documents filed by the company with the Securities and Exchange Commission. For further information please contact: Matt Clawson (Investors), , or Len Hall (Media), , both of Allen & Caron Inc, +1-949-474-4300, for Cardiac Science, Inc.; or Michael Gioffredi, Chief Marketing Officer of Cardiac Science, Inc., +1-949-797-3800, DATASOURCE: Cardiac Science, Inc. CONTACT: Matt Clawson (Investors), , or Len Hall (Media), , both of Allen & Caron Inc, +1-949-474-4300, for Cardiac Science, Inc.; or Michael Gioffredi, Chief Marketing Officer of Cardiac Science, Inc., +1-949-797-3800, Web site: http://www.cardiacscience.com/

Copyright